RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma

PURPOSE: Tafasitamab, an Fc-modified, humanized, anti-CD19 monoclonal antibody, in combination with lenalidomide, demonstrated efficacy in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), in the single-arm, phase II L-MIND study (NCT02399085). RE-M...

Descripción completa

Detalles Bibliográficos
Autores principales: Zinzani, Pier Luigi, Rodgers, Thomas, Marino, Dario, Frezzato, Maurizio, Barbui, Anna Maria, Castellino, Claudia, Meli, Erika, Fowler, Nathan H., Salles, Gilles, Feinberg, Bruce, Kurukulasuriya, Nuwan C., Tillmanns, Sascha, Parche, Stephan, Dey, Debarshi, Fingerle-Rowson, Günter, Ambarkhane, Sumeet, Winderlich, Mark, Nowakowski, Grzegorz S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414300/
https://www.ncbi.nlm.nih.gov/pubmed/34433649
http://dx.doi.org/10.1158/1078-0432.CCR-21-1471

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414300/
https://www.ncbi.nlm.nih.gov/pubmed/34433649
http://dx.doi.org/10.1158/1078-0432.CCR-21-1471

Ejemplares similares